Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series.

Autor:	Balaj K; Department of Psychiatry, Central Michigan University Health, Saginaw, Michigan., Nowinski L; Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Lexington.; Harvard Medical School., Walsh B; Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Lexington., Mullett J; Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Lexington., Palumbo ML; Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Lexington.; Harvard Medical School., Thibert RL; Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Lexington.; Harvard Medical School.; Department of Neurology, Angelman Syndrome Program, Massachusetts General Hospital for Children, Boston, Massachusetts, USA., McDougle CJ; Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Lexington.; Harvard Medical School.; Department of Neurology, Angelman Syndrome Program, Massachusetts General Hospital for Children, Boston, Massachusetts, USA., Keary CJ; Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Lexington.; Harvard Medical School.; Department of Neurology, Angelman Syndrome Program, Massachusetts General Hospital for Children, Boston, Massachusetts, USA.
Jazyk:	angličtina
Zdroj:	Psychiatric genetics [Psychiatr Genet] 2019 Apr; Vol. 29 (2), pp. 51-56.
DOI:	10.1097/YPG.0000000000000218
Abstrakt:	Objectives: Angelman syndrome (AS) is a neurogenetic disorder associated with impaired expression of the ubiquitin-protein ligase E3A gene on chromosome 15. AS results in intellectual disability with limited expressive language, epilepsy, ataxia, sleep impairment, and problematic behavior which may include anxiety. Buspirone is a serotonin (5-HT)1A receptor partial agonist used in the treatment of anxiety disorders and may, therefore, have a treatment role for patients with AS. Methods: We describe three patients who were given open-label buspirone for the treatment of behaviors thought to be related to anxiety. Results: We found significant improvement in symptoms of anxiety with buspirone. Patients tolerated long-term usage of the medication. Conclusion: The findings of this study suggest that buspirone may be effective for the amelioration of behaviors related to anxiety in patients with AS, and well tolerated. Limitations include the open-label nature of these treatments, the small sample size and the absence of a control group.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu